Scarica l'app Stockscreener
37.47
1.26%
-0.48
Dopo l'orario di chiusura:
37.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Artivion Inc Borsa (AORT) Ultime notizie
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
FDA Greenlights Artivion's (AORT) Nexus Aortic Arch System - GuruFocus
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion - Yahoo Finance
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
Needham reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Needham reiterates Artivion stock rating on FDA approval - Investing.com
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com Australia
Artivion stock gets FDA approval for NEXUS stent graft system - Investing.com
FDA approves Artivion’s NEXUS system for aortic arch disease - Investing.com
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $58 - Moomoo
FDA approves Artivion’s NEXUS system for aortic arch disease By Investing.com - Investing.com South Africa
Artivion Says FDA Approves NEXUS Aortic Arch System, Secures Option to Acquire Endospan - marketscreener.com
Artivion announces U.S. FDA approval of the Nexus® aortic arch system - marketscreener.com
Artivion Announces U.S. FDA Approval Of The Nexus® Aortic Arch System - TradingView — Track All Markets
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - ChartMill
Analyst Downgrade: What is the long term forecast for Artivion Inc stockWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Why Artivion (AORT) Stock Is Down Today - Yahoo Finance
Artivion Inc (AORT) Trading Down 3.24% on Apr 6 - GuruFocus
SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT - MarketBeat
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion, Inc. (AORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Holloway Jean F, Artivion SVP, sells $83k in shares - Investing.com
Artivion Inc Com (AORT) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Artivion (NYSE:AORT) Shares Gap DownShould You Sell? - MarketBeat
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
JPMorgan Chase & Co. Has $5.17 Million Position in Artivion, Inc. $AORT - MarketBeat
Is It Too Late To Consider Artivion (AORT) After A 161.6% Three Year Rally? - Yahoo Finance
How The Artivion (AORT) Narrative Is Shifting After A Trimmed Target And Steady Fair Value - Yahoo Finance
Artivion, Inc. (AORT) Stock Forecasts - Yahoo Finance
EDGAR Filing Documents for 0001999371-26-007510 - SEC.gov
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay - Stock Titan
[ARS] ARTIVION, INC. SEC Filing - Stock Titan
Artivion (NYSE:AORT) Shares Down 6.6%What's Next? - MarketBeat
2.40%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):